Search Results

You searched for : Boehringeringelheim

	Boehringer Ingelheim's Investigational Treatment for Schizophrenia receives FDA Breakthrough Therapy Designation The company also announced the planned initiation of the innovative CONNEX Phase III clinical trial program assessing the safety and efficacy of BI 425809 ... May 27
	New Analysis Supports Long-Term Treatment with nintedanib in SSc-ILD Patients1 New Analysis Supports Long-Term Treatment with nintedanib in SSc-ILD Patients1... Nov 07
	Alembic Pharma receives USFDA tentative approval for Empagliflozin and Linagliptin tablets Empagliflozin and Linagliptin tablets, have an estimated market size of US$ 244 million for twelve months ending June 2020... Aug 27
	Boehringer Ingelheim Acquires Northern Biologics, Expanding Immuno-oncology Portfolio Boehringer Ingelheim Acquires Northern Biologicsâ€™ Preclinical Cancer Antibody Pipeline, Expanding Immuno-oncology Portfolio ... May 16
	Boehringer Ingelheim receives positive CHMP opinion for nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease European Medicines Agency (EMA) has adopted a positive opinion recommending granting marketing authorisation for nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease (... Mar 03
	Boehringer Ingelheim Partners with Inflammasome Therapeutics to Develop Novel Therapies for Patients with Retinal Diseases Boehringer Ingelheim and Inflammasome Therapeutics Inc. (Inflammasome) today announced they have entered into a co-development and license agreement to develop up to three therapies ... Sep 21
6 Matching result(s) found!

-Advertisements-

Trending Now
	EV Conference 24---Charging Up for e-mobility Minister Ponnam Prabhakar and Jayesh Ranjan among others to graceJune 14, 2024
	Are we on track to end AIDS, end viral hepatitis and end STIs by 2030?June 14, 2024
	HR Conclave Focusing on Future-Forward Engineering where Engineering and Management students meet their future employees, thus exposing students to real-world HR challenges and innovative solutionsJune 14, 2024
	MAGGI Empowers 10 Women to Bring their Entrepreneurial dreams to lifeJune 13, 2024
	FTCCI announced its Annual Excellence Awards and invites entries, last date is 20th June 2024June 13, 2024
	Bird Flu Cases by Dr Praveen Gupta, Principle Director and Chief of Neurology, Fortis Hospital.June 13, 2024
	Sova Health's $1 Million Seed Funding to Drive Gut Health InnovationJune 13, 2024
	The Vital Role of Early Detection: Kevin Jonas on Battling Skin CancerJune 13, 2024
	Zumutor Biologics Advances Cancer Care with Novel Immunotherapy ZM008: A First-in-Class Anti LLT1 AntibodyJune 13, 2024
	HP Ghosh Hospital Unveils Innovative "Chest Tree" June 12, 2024
	Olympus Enhances Innovation Capabilities by Expanding R&D to Hyderabad, IndiaJune 12, 2024
	From the frontlines: Homeless person won over alcoholism, survived floods and defeated TBJune 12, 2024
	The Role of Hormones in Obesity: Why Men and Women Gain Weight DifferentlyJune 12, 2024
	Silent Killer: How a Young Mother’s Vision Loss Led to a Lung Cancer DiagnosisJune 12, 2024
	TruAlt Bioenergy’s subsidiary, Leafiniti Bioenergy supplies over 1000 tons of Compressed Biogas to AG&P Pratham in just 5 monthsJune 11, 2024
	Southeast Asia's Most Advanced Luxury Postpartum Centre Re'Joy Suites Opens in SingaporeJune 11, 2024
	Poor Muscle Health in Obesity Can be A Major Risk Factor for Early DeathJune 11, 2024
	Machine Learning Uncovers How Organ Ageing Impacts Health and LongevityJune 11, 2024
	Why Education is Essential for Health and LongevityJune 11, 2024
	New Study Reveals Antidepressant Withdrawal Symptoms Less Common but Still SignificantJune 10, 2024

Search Results

Boehringer Ingelheim's Investigational Treatment for Schizophrenia receives FDA Breakthrough Therapy Designation

New Analysis Supports Long-Term Treatment with nintedanib in SSc-ILD Patients1

Alembic Pharma receives USFDA tentative approval for Empagliflozin and Linagliptin tablets

Boehringer Ingelheim Acquires Northern Biologics, Expanding Immuno-oncology Portfolio

Boehringer Ingelheim receives positive CHMP opinion for nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease

Boehringer Ingelheim Partners with Inflammasome Therapeutics to Develop Novel Therapies for Patients with Retinal Diseases

Trending Now